CHI3L1 and astrocytoma (excluding glioblastoma): Akiyama and his group (2014) showed that the CHI3L1 level in the supernatant of the Temozolomide-resistant U87 cell line was upregulated several-fold compared with the level of the parental U87 cell line, and CHI3L1 gene inhibition partially restored sensitivity to Temozolomide [42], which alerts us to the possibility that CHI3L1 might be useful not only as a potential astrocytoma marker but also as a promising therapeutic candidate.